Among treated patients, 42% achieved 5-year event free survival.
Noah Stansfield
Advertisement
Articles by Noah Stansfield
Advertisement
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Slams REGENXBIO's MPS II Gene Therapy RGX-121 With CRL
2
Around the Helix: Cell and Gene Therapy Company Updates – February 11, 2026
3
ImmunoLogic, Episode 8: "Surgery Meets Immunotherapy: A One-Two Punch for Breast Cancer" With Julia C. Tchou, MD, PhD, FACS
4
American College of Physicians Calls for An End of the Term 'Provider' in Policy Paper
5